Last reviewed · How we verify
Pergoveris®
At a glance
| Generic name | Pergoveris® |
|---|---|
| Also known as | r-hFSH/r-hLH, Follitropin alfa/Lutropin alfa, antagonist of gonadotropin releasing hormone, agonist of gonadotropin releasing hormone |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin (PHASE1)
- Ovarian Hyperstimulation and Fibrin Clot Properties. (NA)
- PErsonalized Addition of Recombinant LH in Ovarian Stimulation (PHASE4)
- PERgoveriS In Stratified Treatment for Assisted Reproductive Technique (PHASE3)
- A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)
- Bioequivalence Trial of Liquid Versus Freeze-Dried Pergoveris® in Pituitary Suppressed Healthy Premenopausal Female Subjects (PHASE1)
- Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART) (PHASE3)
- Clinical Outcomes in WHO Type I Anovulatory Women Using r-hFSH+r-hLH in a 2:1 Ratio or hMG-HP (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pergoveris® CI brief — competitive landscape report
- Pergoveris® updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI